Phase 1, Single and Multiple Topically Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of M119102 in Healthy Adult Subjects.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071220006

Enrollment

Registered

2022-04-23

Start date

2022-05-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Interventions

10% M119102 or M119102 placebo will be administered to the back of subjects singlely or twice a day for 2 weeks.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1)Healthy men who are 20 to 44 years of age at the time of informed consent. (2)BMI of 18.5 to 24.9 kg/m2

Exclusion criteria

Exclusion criteria: (1)Individuals with a history or merger of hepatic, renal, cardiac and other cardiovascular, gastrointestinal, hematologic, blood, endocrine, respiratory, or other diseases considered inappropriate for paticipation in the clinical study. (2)Individuals who are judged to be clinically abnormal by the principal (sub) investigator based on clinical tests, vital signs, and electrocardiogram. (3)Individuals who are judged to be unsuitable as subject by the principal (sub) investigator.

Design outcomes

Primary

Measure	Time frame
Safety, Pharmacokinetics	—

Contacts

Public Contact- Clinical Trials Information

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026